The combined effect of RECQL4‐induced changes in soluble factor secretion and MHC‐II downregulation likely facilitates tumour immune evasion, potentially elucidating the attenuated response to ICI therapy in patients exhibiting elevated RECQL4 expression. This evidence concerns the gene RECQL4 and neoplasm.